Skip to main content
TipRanks
Go Ultimate75% OFF

Vitrolife AB (VITR) AI Stock Analysis

2 Followers
SE:VITR

Vitrolife AB

(Nasdaq OMX AB:VITR)

Select Model
Rating:58Neutral
Price Target:SEK 125.00▲(6.20% Upside)
Action:reiterated
Date:10/23/26

The overall score of 58 reflects a company in transition with significant strengths offset by a major financial overhang. The most impactful positive factors are the strong operational momentum and bullish technical trends, driven by robust technology sales and a promising product pipeline, as highlighted in a positive earnings call. The company's ability to generate solid free cash flow provides a crucial buffer. However, the score is heavily constrained by the massive non-cash impairment charges that have devastated reported net income and eroded shareholder equity, resulting in a deeply negative P/E ratio and a precarious financial profile.

Positive Factors
Organic growth and margin improvementBroad-based revenue growth alongside higher EBITDA and gross margins indicates improving operating execution. If sustained, stronger profitability can support reinvestment in products, commercial capabilities and digital tools, reinforcing Vitrolife’s position across fertility-clinic workflows.
Negative Factors
Severe profitability deteriorationDeep operating and net losses show that healthy product-level gross margins are currently overwhelmed by other costs, impairments or restructuring pressure. Unless profitability recovers, losses can erode equity, restrict investment capacity and weaken the durability of otherwise solid revenue and product economics.

Vitrolife AB (VITR) vs. iShares MSCI Sweden ETF (EWD)

-40%-30%-20%-10%0%10%20%30%SE:VITR-16.20%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 12.32B
Dividend Yield
0.93%
Average Volume (3M)
205.32K
Price to Earnings (P/E)
-3.2
Beta (1Y)
0.48
Revenue Growth
-1.94%
EPS Growth
-1223.74%
Country
Sweden
Employees
1,088
Sector
General
Sector Strength
55
Industry
Medical - Devices

Vitrolife AB Business Overview & Revenue Model

Company Description

Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such...

How the Company Makes Money

Vitrolife makes money primarily by selling products and solutions to fertility clinics, IVF laboratories, and other reproductive health customers, with revenue generally derived from recurring consumables and from higher-value equipment and software...

Vitrolife AB Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:20.35%|Next Earnings Date:Jan 28, 2027
Earnings Call SentimentPositive

The call was clearly positive overall. The company reported 6% group organic growth, higher EBITDA and margins, strong technology momentum, progress on restructuring, improving regional IVF and reimbursement trends, and a record innovation pipeline. These positives outweighed the challenges, which included weak Chinese IVF cycles, APAC consumables declines, Middle Eastern softness, higher material and inflationary costs, lower year-over-year operating cash flow and a slight increase in leverage.

Positive Updates

Strong Technology Growth and EmbryoScope Demand
Technologies delivered 21% organic growth in the quarter, driven by all regions. EmbryoScope penetration and utilization increased, the company manufactured and shipped its highest number of EmbryoScopes ever, and management said the technology sales funnel remains strong.

Negative Updates

China IVF Cycles Remained Down
IVF cycles in China, the largest IVF market in APAC, were down year over year and management said this is likely to remain the case in 2027. The company attributed the weakness primarily to demographics, with affordability also a factor, despite improving state aid and reimbursement.

Company Guidance

Management said 21% growth in technologies was “very high” and that maintaining “these type of growth levels” would be “tough,” although the funnel looks good; China’s cycles are “likely to stay that way in 2027,” while most other APAC markets are growing, albeit with “lower growth than we see in Americas or lower growth than we see in Western Europe.” The Americas Latin America headwind is expected to continue until “probably end of Q1,” with declines “slowing” and the trend “flattening out,” while Western Europe consumables growth was “high single digits.” The restructuring program remains “on plan and on time,” targeting annual savings of SEK 65 million, with an 8% gross headcount reduction, a 2.5% headcount addition in sales and marketing, IT and other roles, and a 5.5% net headcount reduction; management said there were “no major changes in headcount additions, but still some more to do.” 2027 is “set to be our best ever year” for the number and size of product launches, although revenue takes “a little bit of time” to filter through, and the time from Gate 4 to launch has been “halved from previous quarters.”

Vitrolife AB Financial Statement Overview

Summary

Financial performance is deeply bifurcated. The income statement is alarming, showing massive net losses (SEK -4.96B TTM) due to significant impairment charges, which have severely eroded shareholder equity. However, the balance sheet remains conservatively financed with low debt, and cash flow generation is a critical strength, with TTM free cash flow of SEK 603M confirming the losses are primarily non-cash. The score reflects this high-risk, high-cash-generation paradox.

Income Statement

18Very Negative

Balance Sheet

55Neutral

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.44B3.44B3.61B3.51B3.23B1.68B
Gross Profit1.98B2.00B2.13B1.98B1.79B1.05B
EBITDA-4.35B-4.39B1.23B-3.19B977.00M579.60M
Net Income-4.96B-5.01B513.00M-3.85B394.00M341.00M
Balance Sheet
Total Assets11.42B11.12B17.45B16.33B20.55B19.43B
Cash, Cash Equivalents and Short-Term Investments860.00M809.00M1.14B861.00M578.00M630.09M
Total Debt1.73B1.60B2.09B2.09B2.23B2.48B
Total Liabilities3.30B3.23B3.81B3.61B3.81B4.09B
Stockholders Equity8.12B7.89B13.64B12.72B16.74B15.32B
Cash Flow
Free Cash Flow603.00M460.00M815.00M638.00M549.00M321.86M
Operating Cash Flow696.00M635.00M907.00M757.00M636.00M384.31M
Investing Cash Flow-215.00M-302.00M-377.00M-124.00M-144.00M-6.52B
Financing Cash Flow-751.00M-553.00M-286.00M-300.00M-582.00M5.75B

Vitrolife AB Technical Analysis

Technical Analysis SentimentPositive
Last Price117.70

Price Trends

50DMA102.05Positive
100DMA96.20Positive
200DMA96.26Positive

Market Momentum

MACD5.11Positive
RSI68.90Neutral
STOCH48.36Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Positive. The current price of 117.70 is above the 20-day moving average (MA) of 114.54, above the 50-day MA of 102.05, and above the 200-day MA of 96.26, indicating a bullish trend. The MACD of 5.11 indicates Positive momentum. The RSI at 68.90 is Neutral, neither overbought nor oversold. The STOCH value of 48.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:VITR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CEVISE:CEVI83OutperformSEK 4.83B35.0315.23%1.36%1.95%-8.91%
SE:GETI.BSE:GETI.B67NeutralSEK 75.53B26.699.13%1.71%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.17B47.925.89%―17.83%330.94%
SE:VITRSE:VITR58NeutralSEK 15.94B-3.21-61.57%0.93%-1.94%-1223.74%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:BACTI.BSE:BACTI.B53NeutralSEK 544.93M86.391.93%―-0.51%―
SE:BICOSE:BICO40UnderperformSEK 1.10B-4.82-28.59%―-5.27%34.38%

* General Sector Average

Performance Comparison

0%50%SE:VITRSE:GETI.BSE:BICOSE:CEVISE:XVIVOSE:BACTI.BDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:VITR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:VITRVitrolife AB117.70-22.85-16.26%
SE:GETI.BGetinge AB (UK)277.3074.5836.79%
SE:BICOBICO Group AB Class B15.58-3.02-16.24%
SE:CEVICellaVision AB202.5050.0932.87%
SE:XVIVOXvivo Perfusion AB196.0031.0018.79%
SE:BACTI.BBactiguard Holding AB15.55-3.20-17.07%

Vitrolife AB Corporate Events

Vitrolife Appoints Nomination Committee for 2027 AGM

Nov 3, 2026

Vitrolife has appointed the Nomination Committee responsible for preparing proposals ahead of its 2027 Annual General Meeting, comprising representatives appointed by major shareholders and the Board Chair. The committee’s formation establishes the c...

Vitrolife names Elin Frostehav as next CEO, sets interim leadership

Oct 26, 2026

Vitrolife Group has announced a leadership transition, appointing Elin Frostehav as its next President and Chief Executive Officer, with her taking up the role no later than May 1, 2027.Senior Vice President Innovation Rickard Ericsson will serve as...

Vitrolife lifts margins and launches major buyback as technologies drive growth

Oct 22, 2026

Vitrolife AB reported third-quarter sales of SEK 884 million, representing 6% organic growth in local currencies excluding exited product lines and 4% total growth in local currencies. Regional performance was strongest in EMEA and the Technologies p...

Vitrolife schedules Q3 2026 report release and investor webcast

Oct 7, 2026

Vitrolife AB will publish its interim report for the third quarter of 2026 on 22 October, with the release scheduled for 08:00 am CET. The company will follow the publication with a conference call and webcast for investors, analysts and financial me...

Vitrolife expands Americas leadership as Erin Schardt joins executive team

Aug 13, 2026

Vitrolife Group has expanded the role of Erin Schardt, appointing her Senior Vice President and General Manager, Americas, with responsibility for both North and South America, and adding her to the Executive Management Team. The move recognizes her...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026